ABSTRACT
INTRODUCTION: The role of laparoscopic ultrasound (LUS) during staging laparoscopy for pancreatic cancers is established but remains debatable in evaluating oesophagogastric cancers. METHODS: A retrospective consecutive case series consisting of patients undergoing staging laparoscopy in two centres (centre A and B) was carried out over a 5-year period (2000-2005). Patients in centre B underwent LUS following laparoscopic assessment using a 7.5-MHz probe. Staging laparoscopy in both centres was performed using a standardised three-port protocol using a 30 degrees laparoscope. All suspicious lesions were sent for histological assessment for confirmation of malignancy. RESULTS: There were 201 patients in centre A (83 gastric, 138 lower oesophageal/junctional cancers) and 119 patients in centre B (51 and 68, respectively). There were no differences between the two centres for patient demographics and tumour site. There was no difference between the two centres for the detection of metastatic disease using laparoscopic assessment alone (A 13% versus B 20%, p = 0.12). However, there was a significant difference (13% versus 28%, p = 0.001) with the additional use of LUS in centre B. The findings in the additional 8% (n = 9) were para-aortic lymphadenopathy (n = 5), liver metastasis (n = 3) and local extension (n = 1). Five had gastric and four lower oesophageal/junctional cancers. The negative predictive value was 6.4% for centre A and 4.5% for centre B. CONCLUSION: The addition of LUS increased the detection rate of metastasis by 8% but there was little impact on the false-negative rate. LUS is useful in detecting metastatic lymphadenopathy beyond the limits of curative resection and liver metastasis.
Subject(s)
Adenocarcinoma/diagnostic imaging , Adenocarcinoma/secondary , Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/pathology , Laparoscopy/methods , Neoplasm Staging/methods , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathology , Ultrasonography, Interventional , Abdominal Neoplasms/diagnostic imaging , Abdominal Neoplasms/secondary , Abdominal Neoplasms/surgery , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Esophageal Neoplasms/surgery , Esophagogastric Junction/diagnostic imaging , Esophagogastric Junction/pathology , Humans , Laparoscopes , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Lymphatic Metastasis/diagnostic imaging , Neoplasm Staging/instrumentation , Pelvic Neoplasms/diagnostic imaging , Pelvic Neoplasms/secondary , Pelvic Neoplasms/surgery , Predictive Value of Tests , Retrospective Studies , Stomach Neoplasms/surgery , Ultrasonography, Interventional/instrumentationABSTRACT
Aneurysms of the splenic artery (SAAs) are a rare complication of portal hypertension in adults. Although the risk of rupture is small, associated mortality is high. Furthermore, circulatory changes that occur following liver transplantation (OLT) may increase the risk of SAA rupture. The incidence in children with portal hypertension is unknown and thus we present our experience with two children who had ruptured SAA, one of whom died. Although there are no accepted methods for routine screening, hepatic angiography should be considered in children with long-standing portal hypertension (more than 10 yr), in order to detect and consider resection of the aneurysms, either before or at the time of liver transplantation.
Subject(s)
Aneurysm, Ruptured/etiology , Hypertension, Portal/complications , Splenic Artery/pathology , Adolescent , Child , Fatal Outcome , Female , Graft Survival , Hematoma/etiology , Humans , Liver Transplantation/adverse effects , Portoenterostomy, Hepatic/adverse effects , Postoperative Hemorrhage/etiology , Rupture, SpontaneousABSTRACT
Awidely held view is that oncolytic agents induce death of tumor cells directly. In this report we review and discuss the apoptosis-inducing effects of chemotherapeutics, the effects of chemotherapeutics on metabolic function, and the consequent effects of metabolic function on immune recognition. Finally, we propose that effective chemotherapeutic and/or apoptosis-inducing agents, at concentrations that can be achieved physiologically, do not kill tumor cells directly. Rather, we suggest that effective oncolytic agents sensitize immunologically altered tumor cells to immune recognition and immune-directed cell death.